NCT01622348

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 44 (actual)
• Sponsor: Idera Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.

Detailed description

To evaluate the safety, tolerability and treatment effect of different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.

Conditions

• Actively Extending Plaque Psoriasis
• Moderate to Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	IMO-3100 at 0.16 mg/kg	IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
DRUG	Saline for Injection	Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
DRUG	IMO-3100 at 0.32 mg/kg	IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection

Timeline

• Start date: 2012-05-01
• Primary completion: 2012-11-01
• Completion: 2012-12-01
• First posted: 2012-06-19
• Last updated: 2018-01-09
• Results posted: 2017-11-13

Locations

13 sites across 1 country: United States